• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CD55 过表达抑制人诱导多能干细胞衍生肾类器官中的补体激活。

Inhibition of complement activation by CD55 overexpression in human induced pluripotent stem cell derived kidney organoids.

机构信息

Department of Internal Medicine-Nephrology, Leiden University Medical Center, Leiden, Netherlands.

Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands.

出版信息

Front Immunol. 2023 Jan 12;13:1058763. doi: 10.3389/fimmu.2022.1058763. eCollection 2022.

DOI:10.3389/fimmu.2022.1058763
PMID:36713440
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9880527/
Abstract

End stage renal disease is an increasing problem worldwide driven by aging of the population and increased prevalence of metabolic disorders and cardiovascular disease. Currently, kidney transplantation is the only curative option, but donor organ shortages greatly limit its application. Regenerative medicine has the potential to solve the shortage by using stem cells to grow the desired tissues, like kidney tissue. Immune rejection poses a great threat towards the implementation of stem cell derived tissues and various strategies have been explored to limit the immune response towards these tissues. However, these studies are limited by targeting mainly T cell mediated immune rejection while the rejection process also involves innate and humoral immunity. In this study we investigate whether inhibition of the complement system in human induced pluripotent stem cells (iPSC) could provide protection from such immune injury. To this end we created knock-in iPSC lines of the membrane bound complement inhibitor CD55 to create a transplant-specific protection towards complement activation. CD55 inhibits the central driver of the complement cascade, C3 convertase, and we show that overexpression is able to decrease complement activation on both iPSCs as well as differentiated kidney organoids upon stimulation with anti-HLA antibodies to mimic the mechanism of humoral rejection.

摘要

终末期肾病是一个全球性的日益严重的问题,其原因是人口老龄化以及代谢紊乱和心血管疾病的患病率增加。目前,肾移植是唯一的治愈方法,但供体器官短缺极大地限制了其应用。再生医学有可能通过使用干细胞来生长所需的组织,如肾组织,来解决短缺问题。免疫排斥对干细胞衍生组织的实施构成了巨大威胁,因此已经探索了各种策略来限制对这些组织的免疫反应。然而,这些研究主要针对 T 细胞介导的免疫排斥,而排斥过程还涉及固有免疫和体液免疫。在这项研究中,我们研究了抑制人类诱导多能干细胞(iPSC)中的补体系统是否可以提供对这种免疫损伤的保护。为此,我们创建了膜结合补体抑制剂 CD55 的基因敲入 iPSC 系,以创造针对补体激活的移植特异性保护。CD55 抑制补体级联反应的中心驱动因子 C3 转化酶,我们表明,在受到模拟体液排斥机制的抗 HLA 抗体刺激时,过表达能够降低 iPSC 以及分化的肾类器官上的补体激活。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21bc/9880527/2f587cc61bd0/fimmu-13-1058763-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21bc/9880527/f3248f691e91/fimmu-13-1058763-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21bc/9880527/3f95d80dc22f/fimmu-13-1058763-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21bc/9880527/8041b10b493e/fimmu-13-1058763-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21bc/9880527/ce34b03f8983/fimmu-13-1058763-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21bc/9880527/2f587cc61bd0/fimmu-13-1058763-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21bc/9880527/f3248f691e91/fimmu-13-1058763-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21bc/9880527/3f95d80dc22f/fimmu-13-1058763-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21bc/9880527/8041b10b493e/fimmu-13-1058763-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21bc/9880527/ce34b03f8983/fimmu-13-1058763-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/21bc/9880527/2f587cc61bd0/fimmu-13-1058763-g005.jpg

相似文献

1
Inhibition of complement activation by CD55 overexpression in human induced pluripotent stem cell derived kidney organoids.CD55 过表达抑制人诱导多能干细胞衍生肾类器官中的补体激活。
Front Immunol. 2023 Jan 12;13:1058763. doi: 10.3389/fimmu.2022.1058763. eCollection 2022.
2
T-Cell Mediated Immune Rejection of Beta-2-Microglobulin Knockout Induced Pluripotent Stem Cell-Derived Kidney Organoids.β2-微球蛋白敲除诱导多能干细胞衍生肾类器官的 T 细胞介导的免疫排斥。
Stem Cells Transl Med. 2024 Jan 12;13(1):69-82. doi: 10.1093/stcltm/szad069.
3
CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.CRISPR/Cas9技术构建的人CD46、CD55和CD59基因敲除细胞系作为补体研究工具
J Immunol Methods. 2018 May;456:15-22. doi: 10.1016/j.jim.2018.02.004. Epub 2018 Feb 12.
4
Generation of a novel decay accelerating factor (DAF) knock-out rat model using clustered regularly-interspaced short palindromic repeats, (CRISPR)/associated protein 9 (Cas9), genome editing.利用成簇规律间隔短回文重复序列、(CRISPR)/相关蛋白 9(Cas9)基因组编辑技术生成新型衰变加速因子(DAF)基因敲除大鼠模型。
Transgenic Res. 2021 Feb;30(1):11-21. doi: 10.1007/s11248-020-00222-x. Epub 2021 Jan 2.
5
Distinct CD55 Isoform Synthesis and Inhibition of Complement-Dependent Cytolysis by Hepatitis C Virus.丙型肝炎病毒不同CD55同工型的合成及其对补体依赖性细胞溶解的抑制作用
J Immunol. 2016 Aug 15;197(4):1127-36. doi: 10.4049/jimmunol.1600631. Epub 2016 Jun 29.
6
Generation of induced pluripotent stem cells as a potential source of hematopoietic stem cells for transplant in PNH patients.诱导多能干细胞的产生作为阵发性睡眠性血红蛋白尿症(PNH)患者移植用造血干细胞的潜在来源。
Ann Hematol. 2016 Oct;95(10):1617-25. doi: 10.1007/s00277-016-2756-1. Epub 2016 Jul 28.
7
Overexpression of Human CD55 and CD59 or Treatment with Human CD55 Protects against Renal Ischemia-Reperfusion Injury in Mice.人CD55和CD59的过表达或用人CD55治疗可保护小鼠免受肾缺血-再灌注损伤。
J Immunol. 2017 Jun 15;198(12):4837-4845. doi: 10.4049/jimmunol.1601943. Epub 2017 May 12.
8
Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack.反义硫代磷酸酯寡核苷酸(S-ODNs)下调CD55和CD46表达可使肿瘤细胞对补体攻击敏感。
Clin Exp Immunol. 2007 Dec;150(3):576-84. doi: 10.1111/j.1365-2249.2007.03507.x. Epub 2007 Sep 28.
9
Decay-Accelerating Factor Creates an Organ-Protective Phenotype after Hemorrhage in Conscious Rats.Decay-Accelerating Factor 在清醒大鼠出血后产生器官保护表型。
Int J Mol Sci. 2022 Nov 5;23(21):13563. doi: 10.3390/ijms232113563.
10
Critical protection from renal ischemia reperfusion injury by CD55 and CD59.CD55和CD59对肾脏缺血再灌注损伤的关键保护作用。
J Immunol. 2004 Mar 15;172(6):3869-75. doi: 10.4049/jimmunol.172.6.3869.

引用本文的文献

1
PD-1-Positive CD8+ T Cells and PD-1-Positive FoxP3+ Cells in Tumor Microenvironment Predict Response to Neoadjuvant Chemoimmunotherapy in Gastric Cancer Patients.肿瘤微环境中PD-1阳性CD8+ T细胞和PD-1阳性FoxP3+细胞可预测胃癌患者对新辅助化疗免疫疗法的反应。
Cancers (Basel). 2025 Jul 21;17(14):2407. doi: 10.3390/cancers17142407.
2
CD55 may be a new target for colorectal cancer treatment.CD55可能是结直肠癌治疗的一个新靶点。
Sci Rep. 2025 Jul 2;15(1):23086. doi: 10.1038/s41598-025-08491-4.
3
Proteomic Analysis of FFPE Tissue Samples Identifies Potential Molecular Mechanisms Mediating Resistance to Radiotherapy in Rectal Cancer.

本文引用的文献

1
Results of Two Cases of Pig-to-Human Kidney Xenotransplantation.猪到人肾异种移植的两例结果。
N Engl J Med. 2022 May 19;386(20):1889-1898. doi: 10.1056/NEJMoa2120238.
2
First clinical-grade porcine kidney xenotransplant using a human decedent model.首例临床级猪肾异种移植采用人尸体模型。
Am J Transplant. 2022 Apr;22(4):1037-1053. doi: 10.1111/ajt.16930. Epub 2022 Jan 20.
3
C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates.C3 补体抑制可预防致敏非人类灵长类动物的抗体介导排斥反应并延长肾移植的存活时间。
福尔马林固定石蜡包埋(FFPE)组织样本的蛋白质组学分析确定了介导直肠癌放疗抗性的潜在分子机制。
J Proteome Res. 2025 Aug 1;24(8):3990-4001. doi: 10.1021/acs.jproteome.5c00114. Epub 2025 Jun 26.
4
Friend or foe: assessing the value of animal models for facilitating clinical breakthroughs in complement research.敌友之间:评估动物模型在推动补体研究临床突破方面的价值。
J Clin Invest. 2025 Jun 16;135(12). doi: 10.1172/JCI188347.
5
Pluripotent stem cell-derived cardiomyocyte transplantation: marching from bench to bedside.多能干细胞衍生的心肌细胞移植:从实验台走向临床应用。
Sci China Life Sci. 2025 May 23. doi: 10.1007/s11427-024-2801-x.
6
The role of alemtuzumab in the development of secondary autoimmunity in multiple Sclerosis: a systematic review.阿仑单抗在多发性硬化症中继发性自身免疫发展中的作用:系统评价。
J Neuroinflammation. 2024 Nov 1;21(1):281. doi: 10.1186/s12974-024-03263-9.
7
Engineering immune-evasive allogeneic cellular immunotherapies.工程化免疫逃逸的同种异体细胞免疫疗法。
Nat Rev Immunol. 2024 Sep;24(9):680-693. doi: 10.1038/s41577-024-01022-8. Epub 2024 Apr 24.
8
T-Cell Mediated Immune Rejection of Beta-2-Microglobulin Knockout Induced Pluripotent Stem Cell-Derived Kidney Organoids.β2-微球蛋白敲除诱导多能干细胞衍生肾类器官的 T 细胞介导的免疫排斥。
Stem Cells Transl Med. 2024 Jan 12;13(1):69-82. doi: 10.1093/stcltm/szad069.
Nat Commun. 2021 Sep 15;12(1):5456. doi: 10.1038/s41467-021-25745-7.
4
Improved production of GTKO/hCD55/hCD59 triple-gene-modified Diannan miniature pigs for xenotransplantation by recloning.通过重新克隆提高 GTKO/hCD55/hCD59 三基因修饰滇南小耳猪的异种移植生产效率。
Transgenic Res. 2020 Jun;29(3):369-379. doi: 10.1007/s11248-020-00201-2. Epub 2020 May 1.
5
Ischemia and Reperfusion Injury in Kidney Transplantation: Relevant Mechanisms in Injury and Repair.肾移植中的缺血再灌注损伤:损伤与修复的相关机制
J Clin Med. 2020 Jan 17;9(1):253. doi: 10.3390/jcm9010253.
6
Integrating gene delivery and gene-editing technologies by adenoviral vector transfer of optimized CRISPR-Cas9 components.通过腺相关病毒载体传递优化的 CRISPR-Cas9 组件实现基因传递和基因编辑技术的整合。
Gene Ther. 2020 May;27(5):209-225. doi: 10.1038/s41434-019-0119-y. Epub 2020 Jan 3.
7
Generation of hypoimmunogenic human pluripotent stem cells.生成低免疫原性的人类多能干细胞。
Proc Natl Acad Sci U S A. 2019 May 21;116(21):10441-10446. doi: 10.1073/pnas.1902566116. Epub 2019 Apr 30.
8
Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility.通过 CRISPR-Cas9 靶向敲除 HLA 基因生成具有增强免疫相容性的 iPSCs。
Cell Stem Cell. 2019 Apr 4;24(4):566-578.e7. doi: 10.1016/j.stem.2019.02.005. Epub 2019 Mar 7.
9
Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients.诱导多能干细胞的低免疫原性衍生物可逃避完全免疫活性同种异体受者的免疫排斥。
Nat Biotechnol. 2019 Mar;37(3):252-258. doi: 10.1038/s41587-019-0016-3. Epub 2019 Feb 18.
10
Progress in multiple genetically modified minipigs for xenotransplantation in China.中国用于异种移植的多种基因编辑小型猪的研究进展。
Xenotransplantation. 2019 Jan;26(1):e12492. doi: 10.1111/xen.12492.